Le Lézard
Classified in: Health, Science and technology
Subject: PDT

New Immobilized Lux Chiral LC/SFC Selector from Phenomenex Delivers Broad Enantioselectivity and Robustness


TORRANCE, Calif., March 19, 2019 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, expands its Lux chiral LC/SFC column family with a third new immobilized chiral media?Lux i-Amylose-3. During the manufacturing of Lux immobilized media, a chemical crosslinking is formed between the polysaccharide and silica support, resulting in a robust column that can withstand a wide range of strong solvents including DMSO, THF, Ethyl Acetate and DCM. This robustness allows for a potential increase in enantioselectivity as new strong solvent systems can provide more mobile phase options during method development. It also allows scientists to keep samples dissolved in strong solvents like DMSO/DCM.

Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, expands its Lux chiral LC/SFC column family with a third new immobilized chiral media?Lux i-Amylose-3.

The new Lux i-Amylose-3 media is available in two particle sizes: 3 µm and 5 µm. The Lux 3 µm i-Amylose-3 is ideal for LC/SFC analytical work and chiral screening, while the larger diameter, Lux 5 µm i-Amylose-3, can be used for analysis and purification work as it is available in analytical (2.1-4.6 mm ID), semi-preparative (10 mm ID) and Axiatm pre-packed preparative columns (21.2-50 mm ID).

"Our new i-Amylose-3 chiral selector, Amylose tris(3-chloro-5-methylphenylcarbamate), has complementary but distinct enantioselectivity in comparison to the Lux i-Amylose-1 and i-Cellulose-5 chiral selectors," explains Ryan Splitstone, Product Marketing Manager for Phenomenex. "It combines the 5-position methyl group of the i-Amylose-1 chiral selector with the electron-withdrawing potential of the 3-position chlorine group of the i-Cellulose-5. Along with strong solvent flexibility, the Lux i-Amylose-3 column's broad enantioselectivity promotes greater chiral separation success and is quickly becoming known as the go-to chiral column that customers start their screens with."

With the addition of Lux i-Amylose-3, the Lux chiral column portfolio now includes three immobilized stationary phases and six coated chiral stationary phases. Altogether, this novel chiral column line delivers a wide and complementary range of enantioselectivity for even the most difficult chiral separation projects under normal phase, reversed phase, polar organic, polar ionic, and SFC separation modes.

To learn more about this amazing new product, check out all the technical content on the Lux i-Amylose-3. And don't forget to browse Phenomenex's full chiral column portfolio!

Contact: Phenomenex Press Room
Tel: (310) 212-0555
Email: [email protected]

The logo for Phenomenex, Inc. (PRNewsfoto/Phenomenex)

SOURCE Phenomenex


These press releases may also interest you

at 09:15
101 Mobility® is thrilled to announce the opening of its newest location in Eden Prairie, marking the introduction of the city's first nationally branded full-service provider of a wide range of mobility equipment. This includes stair lifts, ramps,...

at 09:15
Vibrant Wellness, a leader in specialized diagnostics and personalized health tools, announced today that its Tickborne Testing received approval from The Wadsworth Center, part of the New York State Department of Health.This approval enables Vibrant...

at 09:07
Olympus announced today that it has been awarded a contract for its advanced energy portfolio by Provista Inc. This new, nationwide agreement provides Provista members with negotiated pricing for Olympus® energy products, including the...

at 09:05
Adolescence isn't just a phase; it's a time of unparalleled growth and an opportunity for developing strengths that will influence our adult lives. Recognizing the potential of this developmental stage, Committee for Children a global nonprofit and...

at 09:00
The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp , a global leader of innovative diagnostic and biopharma laboratory services, to serve as its...

at 09:00
LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies,...



News published on and distributed by: